EGFR and non-small cell lung carcinoma: Here, we reported an EGFR-mutated NSCLC patients with MET amplification after afatinib treatment who obtain significant clinical benefit from the combination of aumolertinib with gumarontinib after failure on afatinib plus crizotinib.